ID28070A - Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat - Google Patents

Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat

Info

Publication number
ID28070A
ID28070A IDW20010145A ID20010145A ID28070A ID 28070 A ID28070 A ID 28070A ID W20010145 A IDW20010145 A ID W20010145A ID 20010145 A ID20010145 A ID 20010145A ID 28070 A ID28070 A ID 28070A
Authority
ID
Indonesia
Prior art keywords
propilcarbamate
phosphonoxysi
aminofenil
isobutil
furanil
Prior art date
Application number
IDW20010145A
Other languages
English (en)
Indonesian (id)
Inventor
Ian Gordan Armitage
Andrew David Searle
Herdev Singh
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID28070A publication Critical patent/ID28070A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDW20010145A 1998-07-18 1999-07-15 Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat ID28070A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
ID28070A true ID28070A (id) 2001-05-03

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010145A ID28070A (id) 1998-07-18 1999-07-15 Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat

Country Status (47)

Country Link
US (3) US6514953B1 (cs)
EP (2) EP1240903A3 (cs)
JP (1) JP3437553B2 (cs)
KR (1) KR100694721B1 (cs)
CN (1) CN1188422C (cs)
AP (1) AP2001002039A0 (cs)
AR (1) AR019388A1 (cs)
AT (1) ATE229964T1 (cs)
AU (1) AU766056B2 (cs)
BG (1) BG105253A (cs)
BR (1) BRPI9912156B8 (cs)
CA (1) CA2337857C (cs)
CO (1) CO5090836A1 (cs)
CZ (1) CZ300447B6 (cs)
DE (1) DE69904600T2 (cs)
DK (1) DK1098898T3 (cs)
DZ (1) DZ2845A1 (cs)
EA (1) EA003191B1 (cs)
EE (1) EE200100038A (cs)
ES (1) ES2189450T3 (cs)
GB (1) GB9815567D0 (cs)
GC (1) GC0000105A (cs)
GE (1) GEP20033030B (cs)
GT (1) GT199900111A (cs)
HR (1) HRP20010046A2 (cs)
HU (1) HU229700B1 (cs)
ID (1) ID28070A (cs)
IL (1) IL140824A (cs)
IS (1) IS5808A (cs)
JO (1) JO2114B1 (cs)
MA (1) MA26660A1 (cs)
MY (1) MY122323A (cs)
NO (1) NO329676B1 (cs)
NZ (1) NZ509291A (cs)
OA (1) OA11706A (cs)
PA (1) PA8477801A1 (cs)
PE (1) PE20000869A1 (cs)
PL (1) PL195736B1 (cs)
PT (1) PT1098898E (cs)
SK (1) SK285311B6 (cs)
SV (1) SV1999000096A (cs)
TN (1) TNSN99145A1 (cs)
TR (1) TR200100111T2 (cs)
TW (1) TWI245770B (cs)
WO (1) WO2000004033A1 (cs)
YU (1) YU3401A (cs)
ZA (1) ZA200100417B (cs)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ATE398623T1 (de) * 1999-10-06 2008-07-15 Tibotec Pharm Ltd Hexahydrofuro-2,3-b furan-3-yl-n- 3-,(1,3- benzodioxol-5-ylsulfonyl)(isobutyl)amino -1- benzyl-2-hydroxypropyl carbamat als retrovirusproteasehemmer
UY26380A1 (es) * 1999-10-08 2001-04-30 Smithkline Beecham Corp Inhibidores de fab i
ES2320984T3 (es) * 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
BR0309557A (pt) * 2002-04-26 2005-03-01 Gilead Sciences Inc Inibidores da transcriptase reversa não nucleosìdeos
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
DE602004010291T2 (de) * 2003-09-30 2008-10-09 Tibotec Pharmaceuticals Ltd. Hcv-hemmende sulfonamide
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
MXPA06006899A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
CA2568914C (en) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
PL2319581T3 (pl) 2004-11-26 2015-10-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US8318720B2 (en) * 2006-07-20 2012-11-27 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as Fab I inhibitors
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
MX2009009850A (es) 2007-03-12 2009-09-24 Nektar Therapeutics Conjugados de inhibidor de oligomero-proteasa.
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
UA103329C2 (ru) 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
MX388894B (es) 2009-04-03 2025-03-20 Ocera Therapeutics Inc Fenil acetato de l-ornitina y metodos para elaborar el mismo
EP2432788A1 (en) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
MX375116B (es) 2009-06-08 2025-03-06 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
WO2011001383A1 (en) 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
EP2477996A1 (en) * 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
ME03058B (me) 2010-01-27 2019-01-20 Viiv Healthcare Co Antivirusna terapija
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
EP2614055A2 (en) 2010-09-10 2013-07-17 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
WO2012107937A2 (en) * 2011-02-10 2012-08-16 Mylan Laboratories Ltd Crystalline fosamprenavir calcium and process for the preparation thereof"
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
IN2012DE00082A (cs) 2012-01-10 2015-05-01 Council Scient Ind Res
JP6085026B2 (ja) 2012-06-19 2017-02-22 デビオファーム インターナショナル エスエーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓａ （ｅ）−ｎ−メチル−ｎ−（（３−メチルベンゾフラン−２−イル）メチル）−３−（７−オキソ−５，６，７，８−テトラヒドロ−１，８−ナフチリジン−３−イル）アクリルアミドのプロドラッグ誘導体
JP6797117B2 (ja) 2014-11-24 2020-12-09 ユーシーエル ビジネス リミテッド アンモニア降下療法を用いた肝星細胞活性化関連疾患の処置
CA2995823A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
EP3419628B1 (en) 2016-02-26 2020-10-14 Debiopharm International SA Medicament for treatment of diabetic foot infections
WO2018208677A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
WO2020165407A1 (en) 2019-02-14 2020-08-20 Debiopharm International S.A. Afabicin formulation, method for making the same
JP7418475B2 (ja) 2019-06-14 2024-01-19 デバイオファーム インターナショナル エス．エー． バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EE200000386A (et) * 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
EP1126847A1 (en) * 1998-11-04 2001-08-29 PHARMACIA & UPJOHN COMPANY Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors

Also Published As

Publication number Publication date
PL345620A1 (en) 2002-01-02
OA11706A (en) 2005-01-13
HRP20010046A2 (en) 2002-02-28
CO5090836A1 (es) 2001-10-30
CN1188422C (zh) 2005-02-09
PE20000869A1 (es) 2000-09-08
US20030096795A1 (en) 2003-05-22
SK285311B6 (sk) 2006-10-05
HK1034261A1 (en) 2001-10-19
DE69904600D1 (de) 2003-01-30
IL140824A (en) 2004-09-27
CA2337857C (en) 2011-01-25
EP1098898A1 (en) 2001-05-16
PL195736B1 (pl) 2007-10-31
IL140824A0 (en) 2002-02-10
ZA200100417B (en) 2002-02-27
HUP0103432A3 (en) 2003-01-28
TR200100111T2 (tr) 2002-02-21
MA26660A1 (fr) 2004-12-20
BRPI9912156B1 (pt) 2016-07-26
KR100694721B1 (ko) 2007-03-15
JO2114B1 (en) 2000-05-21
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
HUP0103432A2 (hu) 2002-04-29
NZ509291A (en) 2003-05-30
NO20010282D0 (no) 2001-01-17
HU229700B1 (en) 2014-05-28
DZ2845A1 (fr) 2003-12-01
IS5808A (is) 2001-01-12
TNSN99145A1 (fr) 2005-11-10
EA003191B1 (ru) 2003-02-27
CZ2001219A3 (cs) 2001-07-11
EP1098898B1 (en) 2002-12-18
GB9815567D0 (en) 1998-09-16
EP1240903A2 (en) 2002-09-18
JP2003521447A (ja) 2003-07-15
DK1098898T3 (da) 2003-04-07
NO20010282L (no) 2001-03-07
MY122323A (en) 2006-04-29
AU5037999A (en) 2000-02-07
PA8477801A1 (es) 2000-05-24
DE69904600T2 (de) 2003-11-13
ATE229964T1 (de) 2003-01-15
AR019388A1 (es) 2002-02-13
AU766056B2 (en) 2003-10-09
CN1324363A (zh) 2001-11-28
AP2001002039A0 (en) 2001-03-31
TWI245770B (en) 2005-12-21
CA2337857A1 (en) 2000-01-27
GT199900111A (es) 2001-01-05
YU3401A (sh) 2005-06-10
EE200100038A (et) 2002-06-17
JP3437553B2 (ja) 2003-08-18
GEP20033030B (en) 2003-07-25
SV1999000096A (es) 2000-07-06
SK762001A3 (en) 2001-10-08
WO2000004033A1 (en) 2000-01-27
BG105253A (en) 2001-12-29
EP1240903A3 (en) 2003-02-12
GC0000105A (en) 2005-06-29
EA200100053A1 (ru) 2001-08-27
ES2189450T3 (es) 2003-07-01
BRPI9912156B8 (pt) 2021-05-25
BR9912156A (pt) 2001-04-10
NO329676B1 (no) 2010-11-29
PT1098898E (pt) 2003-04-30
US6514953B1 (en) 2003-02-04
CZ300447B6 (cs) 2009-05-20

Similar Documents

Publication Publication Date Title
ID28070A (id) Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat
NO982097D0 (no) Peptider
NO982098L (no) Peptider
DE69724756D1 (de) Gelenkige zusammensetzbare Spielfigur
FI102434B (fi) Kahden taajuuden antenni
TR970073A2 (tr) Alfa adrenerjik resentör antagonistleri olarak pirimidindion pirimidintrion,triazindion, tetrahidrokinazolindion türevleri.
DE69838000D1 (de) Weiche,bifokale kontaktlinse
ITBO980146A0 (it) Pacchetto per sigarette.
EA200000208A1 (ru) Иммуномодулятор с антимикробной и антимикобактериальной активностью, способ его получения и лекарственный препарат для лечения микобактериозов, хронических неспецифических заболеваний легких, заболеваний, передающихся половым путем, и иммунодефицита на их основе
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
DE69933647D1 (de) Rekombinante lysophosphatidsäure - phosphatase.
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
DE59806925D1 (de) Satbilisierter, kubischer, flexibler Behälter
ID18458A (id) Pembuatan alifatik alfa, omega-amino nitril
IT1312093B1 (it) Condimento confezionato.
NL1008191A1 (nl) Afdichting.
ES1047984Y (es) Corchete de ortodoncia.
NL1012028A1 (nl) Aminozuursequentie.
IT1303333B1 (it) Sottopiede per calzature.
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
ES1036589Y (es) Maquina surqueadora estanqueadora.
IT245874Y1 (it) Sostegno-espositore per calzature.
SE9802536D0 (sv) Novel peptides
SE9604329D0 (sv) Specialsko för segling mm
NO982498D0 (no) Fleksibel, fjµrende svepe